HK:2186 Stock Latest News
PremiumCompany AnnouncementsLuye Pharma Reports Mixed Financial Results for 2024 Luye Pharma Group Schedules Board Meeting to Approve Annual Results and Dividend Luye Pharma upgraded to Neutral from Sell at Goldman Sachs PremiumCompany AnnouncementsLuye Pharma Bolsters Liquidity with $50M Bond Issue Luye Pharma Gains Approval for Cancer Drug Zepzelca Luye Pharma Gains Ground with New Drug Inclusions PremiumCompany AnnouncementsLuye Pharma Group to Issue $150M Convertible Bonds Luye Pharma Group Reports Strong Mid-Year Financials Luye Pharma Sets Date for Financial Results Review